PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31506605-4	2020	Preclinical studies using multiple in vitro nAR-negative BCa cell lines and an in vivo mouse model all demonstrated that targeting this newly identified DHT/mAR-SLC39A9/Galphai/MAPK/MMP9 signaling with small molecules mAR-SLC39A9-shRNA or Galphai-shRNA, and not the classic antiandrogens including enzalutamide, bicalutamide, or hydroxyflutamide, could suppress nAR-negative BCa cell invasion.	nar	44-47	solute carrier family 39 (zinc transporter), member 9	Mus musculus	161-168	
31506605-4	2020	Preclinical studies using multiple in vitro nAR-negative BCa cell lines and an in vivo mouse model all demonstrated that targeting this newly identified DHT/mAR-SLC39A9/Galphai/MAPK/MMP9 signaling with small molecules mAR-SLC39A9-shRNA or Galphai-shRNA, and not the classic antiandrogens including enzalutamide, bicalutamide, or hydroxyflutamide, could suppress nAR-negative BCa cell invasion.	nar	362-365	solute carrier family 39 (zinc transporter), member 9	Mus musculus	161-168